Turing Pharmaceuticals AG announced its official launch along with news of three acquisitions for its commercial operations and development pipeline. The company also introduced its senior management team.

New York-based Turing will focus on developing and commercializing treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options.

Turing’s founder and executive chairman is Martin Shkreli, founder and former CEO of Retrophin, Inc.

In addition to Mr. Shkreli, Turing has assembled a management team comprised of senior executives, including: Howard Dorfman, SVP, general counsel; Hass Patel, VP for chemistry, manufacturing and controls; Nicholas Pelliccione, VP, regulatory affairs; Michael Harrison, chief financial officer; Nancy Retzlaff, chief commercial officer; and Megan Roberts, VP and product leader for Vecamyl.

Simultaneous to its launch, Turing announced the acquisition of three assets from Retrophin:  an intranasal formulation of ketamine, Syntocinon (oxytocin nasal solution) and Vecamyl (mecamylamine HCl tablets).

Turing is developing its new intranasal formulation of ketamine for a variety of psychiatric indications. The company is making significant investments in a novel delivery mechanism and other innovations to develop ketamine for the treatment of several serious psychiatric conditions for patients who currently have limited treatment options, and expects to commence clinical trials in the coming year.

Turing’s plans further include a development program for Syntocinon in addressing multiple indications across several therapeutic areas.

The acquisition of Vecamyl nprovides Turing with its first FDA-approved product and revenue stream, which it plans to grow through a robust clinical development and education program.